ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:
Jefferies London Healthcare Conference (In Person)
Presentation Time | Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST) |
Presenters | Mr. Raj Kannan, CEO |
Webcast link | https://wsw.com/webcast/jeff287/imab/1828028 |
Meetings | One-on-one and small group meetings: Nov 14 – 16, 2023 |
Management | Mr. Raj Kannan, CEO |
For more information, please contact your Jefferies representative.
Piper Sandler 35th Annual Healthcare Conference (In Person)
Presentation Time | Thursday, November 30th at 8:30 a.m. EST |
Presenters | Mr. Raj Kannan, CEO |
Meetings | One-on-one and small group meetings: Nov 28 – 30, 2023 |
Management | Mr. Raj Kannan, CEO |
For more information, please contact your Piper Sandler representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, X, formerly known as Twitter, and WeChat.
I-Mab Contacts
Investors | Media |
Tyler Ehler | Gigi Feng |
Senior Director, Investor Relations | Chief Communications Officer |
| Last Trade: | US$0.89 |
| Daily Change: | 0.04 4.44 |
| Daily Volume: | 30,902 |
| Market Cap: | US$72.780M |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
